FIRST AMENDMENT TO MARKETING, DISTRIBUTION AND SUPPLY AGREEMENTMarketing, Distribution and Supply Agreement • March 16th, 2007 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO MARKETING, DISTRIBUTION AND SUPPLY AGREEMENT (the “First Amendment”) made as of the 10th day of January, 2007 (the “Effective Date”) among DUSA PHARMACEUTICALS, INC., a New Jersey corporation having a principal office and place of business at 25 Upton Drive, Wilmington, Massachusetts, USA 01887 (hereinafter called “DUSA”), and DAEWOONG PHARMACEUTICAL CO., LTD, a Korean corporation having a principal office and place of business at 163-3 Samsung-dong Gangnam-gu, Seoul, Korea, (hereinafter called “DAEWOONG”) and DNC DAEWOONG DERMA & PLASTIC SURGERY NETWORK COMPANY, a wholly-owned Korean subsidiary of DAEWOONG PHARMACEUTICAL CO., LTD having a principal office and place of business at 163-3 Samsung-dong Gangnam-gu, Seoul, Korea (hereinafter called “DNC” and collectively with DAEWOONG hereinafter called “D&D”).
BETWEENMarketing, Distribution and Supply Agreement • March 10th, 2006 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations
MARKETING, DISTRIBUTION AND SUPPLY AGREEMENT AMONG DUSA PHARMACEUTICALS, INC., DAEWOONG PHARMACEUTICAL CO., LTD., AND DNC DAEWOONG DERMA & PLASTIC SURGERY NETWORK COMPANY DATED January 4, 2007Marketing, Distribution and Supply Agreement • March 16th, 2007 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations
AMENDMENT NO. 1 TO THE MARKETING, DISTRIBUTION AND SUPPLY AGREEMENTMarketing, Distribution and Supply Agreement • November 9th, 2007 • Dusa Pharmaceuticals Inc • Pharmaceutical preparations • New York
PRESTWICK PHARMACEUTICALS, INC. - and - OVATION PHARMACEUTICALS, INC. Marketing, Distribution and Supply Agreement for XenazineMarketing, Distribution and Supply Agreement • February 26th, 2010 • Biovail Corp International • Pharmaceutical preparations • New York
This MARKETING, DISTRIBUTION AND SUPPLY AGREEMENT (this “Agreement”) is dated as of September 16, 2008 (the “Effective Date”) by and between Prestwick Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware and having a principal place of business at 1825 K Street NW, Suite 1475, Washington, D.C. 20006 (“Prestwick”), and Ovation Pharmaceuticals, Inc., a company incorporated under the laws of the State of Illinois and having a principal place of business at Four Parkway North, Deerfield, Illinois 60015 (“Distributor”). Prestwick and Distributor are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
